The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
April 22nd 2024
Prolonged modified fasting, in a multimodal medical approach, may help patients with fibromyalgia improve pain and psychosomatic symptoms.
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 2024
Register Now!
EGPA: Highlighting the Patient Journey to Improve the Differential Diagnosis and Accelerate the Initiation of Guideline-Based Care
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical Consultations™: Optimal Approaches to Recognizing and Treating ANCA-Associated Vasculitis
View More
Autoimmune Disease Increases Risk of Developing Cardiovascular Disease
Although investigations have been performed on the association between inflammatory conditions and cardiovascular events, the effect of different conditions on cardiovascular diseases has not been analyzed on a large scale.
Patients with PsA More Likely to Experience Side Effects of Methotrexate
"This risk-to-benefit profile has a different connotation for patients because, although a therapy may improve certain aspects of their disease, it may also have a substantial impact on their quality of life.”
Paul M Peloso, MD, MSc: Izokibep Significantly Improves Symptoms of Psoriatic Arthritis
Rheumatology Network interviewed Paul M. Peloso, MD, MSc, Chief Medical Officer at Acelyrin, to discuss recent phase 2 data examining the safety and efficacy of izokibep in the treatment of psoriatic arthritis.
Pulmonary Involvement More Likely in Treatment-Naïve Pediatric Patients
Although pulmonary complications in pediatric patients may cause functional impairment and increase mortality, studies detecting lung involvement in children with treatment-naïve, newly diagnosed patients with rheumatic disease are scarce.
FDA Approves Citrate-Free, High-Concentration Adalimumab Biosimilar Adalimumab-bwwd
The US Food and Drug Administration approved of the citrate-free, high-concntration (100 mg/mL) formulation of adalimumab-bwwd, a biosimilar of adalimumab, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.
Psoriatic Arthritis Remission Strongly Associated with Alleviation of Psoriasis Symptoms
“Given the complex nature of PsA, patients should also be involved in defining their treatment goals, as every patient may have different perspectives on the target for therapy and the means to achieve it.”
Rheumatoid Arthritis Quiz: Vaccinating Patients Taking Immunosuppressive Medications
August 12th 2022Immunosuppressive medication can interfere with the immune response to vaccines, so treatment may need to be held or the timing or type of vaccinations amended. Test your knowledge of vaccinating rheumatoid arthritis patients taking immunosuppressive therapies in this quiz.
COVID-19 Vaccine Minimally Impacts Risk of Gout Flares
"COVID-19 vaccines are effective against severity of SARS-COV-2 infection, but there has been a concern regarding their effect on the risk of flares in patients with gout, which are associated with health-related quality of life, healthcare resource utilization, and work productivity."